Winston Pharmaceuticals, Inc (WPHM) Fair Value & Analysis
Healthcare · US · Market cap $7.7K
Winston Pharmaceuticals, Inc
WPHM · US
Strengths
Risks
Fair value as of: Aug 23, 2026
From 1 valuation models · updated yesterday
Below-average quality, currently priced close to our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 23, 2026.
How to read this chart
60‑month range $0.0001 – $0.3000 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 23, 2026.
Analysis
Winston Pharmaceuticals, Inc (WPHM) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $1.4M. Revenue declined 6.8% year over year. Fundamentals as of Aug 23, 2026
The share trades about 67% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, WPHM screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when WPHM reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management.
Full company description
Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management. It focuses on pain indications, such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo-and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications. Winston Pharmaceuticals, Inc. was formerly known as Winston Laboratories, Inc. and changed its name to Winston Pharmaceuticals, Inc. in November 2008. The company was incorporated in 1998 and is headquartered in Vernon Hills, Illinois.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2006 – FY2009 · reported fiscal years
Winston Pharmaceuticals, Inc reported revenue of $1.4M in FY2009 versus $294K in FY2006, a compound +67.9%/yr. Reported net income was −$2.7M in FY2009.
Watch WPHM: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 638 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,881 | ₹1,169 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
| Laurus Labs Limited LAURUSLABS | ₹1,823 | ₹344.84 | -81% |
Compare Winston Pharmaceuticals, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Winston Pharmaceuticals, Inc (WPHM) overvalued or undervalued?
What is the fair value of WPHM?
What is the quality score of WPHM?
What is the revenue of Winston Pharmaceuticals, Inc (WPHM)?
What is the net profit margin of WPHM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Winston Pharmaceuticals, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.